continu growth across segment
maintain buy rate agil upgrad
tp deriv tp base forward
price-to-earnings multipl adjust ep
provid upsid potenti
estim top line growth
estim base follow factor double-digit
growth pharma environment forens continu
growth across busi segment newli launch
product agil
revenu increas
due growth across busi also
strong growth pharma environment forens end-
basi net incom
includ discret tax benefit ep
adjust ep
agil lsag revenu increas
demand pharma environment
forens market led result lsag oper margin
quarter
agil acg revenu increas
growth excel across servic consum
region end-market acg oper margin
quarter
compani nameagilenttickerastock ratingbuyunchangedindustri viewoverweightpositivepric may week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha inc| may
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
dcg revenu increas
growth due strength pharma
clinic diagnost end-market led excel
agil complet acquisit
develop cutting-edg cell analysi solut agil
announc two new ga chromatograph flagship
new mid-rang
agil launch first pharmdx kit dako
omni platform eu
agil launch new softwar servic offer
allow custom remot manag asset base
applic sampl volum well monitor
multi-vendor instrument util across
agil expect revenu rang
non-gaap ep expect
rang agil
expect revenu rang
non-gaap ep rang
current price-to-earnings averag
price-to-earnings due volatil stock price price-to-earnings
trail
expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date apr last split factor new per last split date inform agil technolog inc| may
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement revenu total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli inc| may
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item agil inc| may
net cash inflow oper activ compar
agil paid variabl incent pay program net cash paid incom tax
net cash use invest activ compar net cash use invest
activ invest properti plant equip
agil invest acquisit net cash acquir compar
acquisit period last year
net cash use financ activ compar cash provid financ activ
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc| may
agil deliv strong perform quarter due continu
growth revenu earn
agil revenu increas compar
foreign currenc movement unfavor impact
revenu ppt compar period last year servic
revenu increas
cog increas compar
total gross margin rel flat
compar period last year gross margin reflect higher sale
volum lower share-bas compens expens off-set increas
wage higher expens relat tariff higher amort expens
 expens increas compar
increas due increas program spend
new product relat busi addit higher wage
addit expens relat acquir busi compar
spend period last year
increas
compar
increas
compar
sg expens increas compar
increas due increas wage higher
acquisit integr cost partial off-set lower share-bas
compens expens favor currenc impact
oper incom increas compar
oper margin compar
growth impact higher sale volum lower
share-bas compens expens partial off-set increas wage higher
acquisit integr cost higher expens relat tariff higher
amort expens intang asset
interest incom compar
interest expens compar
expens net compar
benefit tax rate compar
provis tax
net incom
compar
net loss
net incom compar net loss
net incom includ discret tax benefit
adjust net incom increas ep
compar non-gaap ep
increas
agil gener oper invest paid
dividend repurchas share
revenu geographi
 contribut total revenu
europ contribut total revenu
asia pacif region contribut total revenu
gaap ep
compar
revenu geographi
america region deliv high single-digit core growth commerci
team continu execut high level asia outsid china grew low
doubl digit europ china grew low single-digit difficult
comparison respect
revenu type instrument revenu quarter contribut
total revenu consum servic informat contribut total
revenu
revenu major market analyt laboratori contribut total
revenu dx clinic market contribut total revenu
revenu end-market
agil strong growth quarter due gain pharma
europ china grew
low single-digit
difficult comparison
respect
contribut total
revenu dx
contribut total
revenu
chemic forens clinic govern inc| may
revenu end-market
agil strong growth quarter due gain pharma dx
clinic environmental/forens end-market
grew y/i core basi
pharma revenu grew broad-bas strength across
segment region continu strength bio-pharma
applic cell analysi nasd
academia government flat double-digit compar
environment forens revenu increas due broad-bas
growth demand gc gc/m spectroscopi consum
food revenu decreas china regulatori transit move
chemic increas compar instrument
flat continu momentum aftermarket offer
diagnost clinic end market revenu grew y/i core basi
due broad-bas strength healthi perform patholog relat
busi workflow portfolio
revenu grew
broad-bas
strength across
segment region
continu
strength bio-pharma
analysi nasd
compar
life scienc appli market group lsag
life scienc appli market busi provid application-focus
solut includ instrument softwar enabl custom
identifi quantifi analyz physic biolog properti
substanc product well enabl custom clinic life
scienc research area interrog sampl molecular cellular
lsag revenu increas compar
foreign currenc movement overal
unfavor impact revenu ppt
revenu growth led continu strength pharmaceut
market also due strong growth academia govern
environment market partial off-set declin growth food
chemic energi market
gross margin oper margin
compar incom oper
compar
chromatograph
flagship
new mid-rang
agil announc two new ga chromatograph flagship
new mid-rang incorpor intellig predict
technolog allow custom remot connect autonom
monitor maxim laboratori product
analyt scientist rank agil laser direct infrar
chemic imag breakthrough chemic imag
spectral analysi top innov
agil complet acquisit develop
agil crosslab busi span entir lab extens consum
servic portfolio design improv custom outcom
product categori consum includ gc lc column sampl
prepar product custom chemistri larg select laboratori
instrument suppli servic includ start-up oper train
complianc support softwar servic well asset manag
consult servic help increas custom product
agil crosslab group revenu increas
compar foreign currenc movement
overal unfavor impact revenu ppt compar
period last year
revenu grew across key end market strong growth
academia govern forens environment
gross margin increas compar
oper margin compar
incom oper compar
agil launch new softwar servic offer allow
custom remot manag asset base applic sampl
volum well monitor multi-vendor instrument util across
entir lab
revenu increas
compar
key end market
strong growth
academia
environment
diagnost genom group dgg
diagnost genom busi includ genom nucleic acid contract
manufactur patholog companion diagnost reagent
partnership busi compris five area activ provid
solut includ reagent instrument softwar consum
enabl custom clinic life scienc research area
interrog sampl cellular molecular level
dcg revenu increas compar
foreign currenc movement overal
unfavor impact revenu ppt
revenu growth within diagnost clinic market continu
improv across busi led strong perform nucleic
gross margin compar
oper margin compar
incom oper increas compar
compar
pharmdx kit
dako omni
platform eu
agil launch first pharmdx kit dako omni platform
eu build prepar new frederick colorado nasd
agil recent action profit growth plan includ
deliv agil agil initi
multi-year program increas effici custom focu
oper margin expand
portfolio invest go-to-market capabl
launch new softwar servic offer allow custom
remot manag asset base applic sampl volum
well monitor multi-vendor instrument util across
complet acquisit develop cutting-edg
announc two new ga chromatograph flagship
remot connect autonom monitor maxim
analyt scientist rank agil laser direct infrar
chemic imag breakthrough chemic imag
spectral analysi top innov
launch first pharmdx kit dako omni platform
eu
softwar servic
offer allow
custom remot
manag asset base
applic sampl
volum well
monitor multi-
util across
revenu expect rang
adjust ep expect rang
dilut share count remain
revenu expect
rang
adjust ep expect
rang
net interest income/expens net expens
inclus keysight bill impact
sharehold return dividend novemb author
repurchas share depend market condit
revenu expect rang
adjust ep expect rang
agil revenu increas perform
highlight double-digit growth agil crosslab
diagnost genom group end-market perspect
result led double-digit growth pharma clinic diagnost
environment forens market
agil lsag revenu increas demand
pharma environment forens market led result lsag
oper margin quarter
agil acg revenu increas growth
excel across servic consum region end-market acg
oper margin quarter
dcg revenu increas growth due
strength pharma clinic diagnost end-market led
agil complet acquisit develop cutting-edg
cell analysi solut agil announc two new ga chromatograph
flagship new mid-rang
agil launch new softwar servic offer allow custom
remot manag asset base applic sampl volum well
monitor multi-vendor instrument util across entir lab
agil start strengthen best-in-class portfolio bring new
solut servic custom help gain new insight
achiev greater product lab
strengthen best-
servic
custom help
gain new insight
product lab
non- reconcili
non- reconcili
non- reconcili
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm basi compar
revenu growth ttm basi compar
net margin ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth agil inc| may
mrqgross mrqcog mrqsg mrqoper mrqnet mrqr sale agil inc| may
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset agil technolog inc| may
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item agil technolog inc| may
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale purchas investment- sale investment- issuanc stock- repurchas net issuanc prefer stock- net issuanc debt- net chang capit free inc| may
current price-to-earnings averag price-to-earnings due volatil stock price
price-to-earnings trail expect forward price-to-earnings
multipl
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluepric row associ vanguard group inc oppenheim fund wellington manag compani artisan partner limit state mutual automobil insur fmr top mutual fund holdersholdersharesd report outvaluevanguard total stock market price row mid cap growth vanguard spdr etf price row vanguard institut fund-institut fidel oppenheim main street ishar vanguard growth inc| may
developmentsagil complet acquisit acea biosciencesnovemb inc announc complet acquisit acea bioscienc inc acea develop cutting-edg cell analysi tool cash acquisit bring togeth two pioneer cellular function metabol measur focus real-tim live cell analys agil introduc new icp-m analyz solutionnovemb inc introduc new turnkey solut analyz water qualiti theagil icp-m analyzeren environment laboratori set run regul method matter day rather week even month new water analyz packag repres end-to-end workflow analyz water qualiti base regul establish environment protect agenc intern organ standard agil introduc groundbreak uv-vi spectrophotomet biomed academ laboratoriesnovemb inc introduc cari uv-vi system innov spectrophotomet design help life scienc pharma biopharma research commun simplifi analys optim laboratori product ultim help bring new therapeut market faster agil introduc uniqu gener sequencing-bas preimplant genet test pgt solutionoctob inc announc introduct agil onepgt genome-wid next-gener sequenc solut preimplant genet test pgt onepgt allow parallel detect multipl monogen disord pgt-m transloc pgt-sr aneuploidi pgt-a singl biopsi inc| may
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
agil
compar
roa roi roe
ttm
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit agil inc| may
consensu view analyst trend stock
forecast agil
compar
 average
forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonaindustri avg avgprice/earn yield inc| may
consensu view analyst trend stock
averag earn current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr agil technolog inc| may
price target summarycrispidea suissedowngradeneutralund robinson co downgrademarket performrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext agil inc| may
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price volatil quarter surg later declin
stock gave return period
stock price volatil surg april howev stock
declin later
rang stock stock gave return year
stock price show upward trend past gave return past
stock price show huge growth volatil
agil deliv strong result quarter growth revenu growth adjust
ep growth led end-market growth pharma environment forens growth
across busi segment expect tp reach
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
